Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer
Natali Gulbahce(University of California, San Francisco), Brock A. Peters(Complete Genomics (United States)), Rebecca Yu Zhang(Broadcom (United States)), Qing Mao(Broadcom (United States)), Serban Ciotlos(Broadcom (United States)), Emily Park(Advanced Cell Diagnostics (United States)), Xingpeng Chen(Lanzhou University), Radoje Drmanac(Complete Genomics (United States)), Mark Jesus M. Magbanua(University of California, San Francisco), Daniel M. Hayden(Broadcom (United States)), John W. Park(University of California, San Francisco), Rick Tearle(Broadcom (United States)), Misha R. Agarwal(Broadcom (United States)), Hope S. Rugo(City of Hope), Zhenyu Li(BGI Group (China)), Yuxiang Li(Sun Yat-sen University), Jia Liu(Sun Yat-sen University), Yanxiang Chen(Broad Institute), Robert Chin(Broadcom (United States)), Snezana Drmanac(BGI Group (China)), Xuhao Luo(Broadcom (United States)), Katharine Lee(Broadcom (United States))
Cited by 52
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k